Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q3 2021

Q3 2021 biggest moves
  • NUVLNUVL

    NUVALENT

    New listing

    8.5% of portfolio

  • ZBHZBH

    Zimmer Biomet

    Sold out

    was 1.0% of portfolio

  • QDELQDEL

    QuidelOrtho

    Sold out

    was 0.9% of portfolio

  • NBIXNBIX

    Neurocrine Biosciences

    Added 58%

    now 2.1% of portfolio

109 changes in all

Top Holdings133 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

19.3M$436.1M8.5%——
1 qtr
New
96
VTRS

Viatris Inc.

18.8M$255.1M5.0%$14.37-23.57%
4 qtrssince 2020-Q4
Unchanged
0
??
INVITAE CORPDelisted
Bond
163.4M$199.6M3.9%——
5 qtrssince 2020-Q3
Unchanged
0
AHCO

AdaptHealth Corp.

8.1M$188.7M3.7%$24.65-5.53%
8 qtrssince 2019-Q4
Increased
62
??
CAREMAX INCDelisted
16.8M$162.1M3.2%——
2 qtrssince 2021-Q2
Unchanged
0
157.4M$143.8M2.8%——
5 qtrssince 2020-Q3
Unchanged
0
??
NATERA INCDelisted
Bond
45M$135.2M2.6%——
2 qtrssince 2021-Q2
Unchanged
0
??
GLAUKOS CORPDelisted
Bond
108M$129.6M2.5%——
2 qtrssince 2021-Q2
Increased
61
80M$110.5M2.2%——
3 qtrssince 2021-Q1
Unchanged
0
NBIX

Neurocrine Biosciences, Inc.

1.1M$109.6M2.1%$96.76-0.88%
3 qtrssince 2021-Q1
Increased
73
52.5M$109.2M2.1%——
2 qtrssince 2021-Q2
Unchanged
0
ORGO

Organogenesis Holdings Inc.

7.5M$106.3M2.1%$17.19-17.14%
3 qtrssince 2021-Q1
Increased
53
SMFR
SMFRDelisted

GENEDX HOLDINGS CORP

13.8M$105.1M2.1%——
1 qtr
New
78
OMIC
OMICDelisted

SINGULAR GENOMICS SYSTEMS IN

9.1M$102M2.0%——
2 qtrssince 2021-Q2
Unchanged
0
??
NUVASIVE INCDelisted
Bond
97M$98.8M1.9%——
2 qtrssince 2021-Q2
Unchanged
0
81.6M$87.7M1.7%——
1 qtr
New
68
??
INSULET CORPDelisted
Bond
57.6M$80.4M1.6%——
4 qtrssince 2020-Q4
Unchanged
0
ISEE
ISEEDelisted

IVERIC BIO INC

4.9M$79M1.5%——
8 qtrssince 2019-Q4
Decreased
0
LUNG

Pulmonx Corporation

2M$73M1.4%$49.27-26.97%
4 qtrssince 2020-Q4
Increased
53
LRMR

Larimar Therapeutics, Inc.

5.8M$67.2M1.3%$12.49-7.71%
6 qtrssince 2020-Q2
Unchanged
0
$5.1B
AUM
133
Positions
Q3 2021
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2020-Q2$3,433,887,0008.97378164477%
2020-Q3$4,106,901,00019.5991889075%
2020-Q4$5,059,782,00023.2019471616%
2021-Q1$4,758,345,000-5.95750963184%
2021-Q2$5,629,668,00018.3114717407%
2021-Q3$5,123,921,000-8.98360258545%
Activity profile
$ moved · Q3'21
New38%Increased14%Decreased14%Exited34%
Composition
Equity vs derivatives
Equity>99%Puts<1%Calls0%
Holding period
Avg 2.9 quarters
<1Q21%1-4Q44%1-2Y35%2Y+0%

Deerfield Management Company, L.P. manages $5.1B across 133 positions as of Q3 2021. Top holdings: NUVL (8.5%), VTRS (5.0%), INVITAE CORP (3.9%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$5B
NUVL8.51%
VTRS4.98%
INVITAE CORP3.90%
AHCO3.68%
CAREMAX INC3.16%
AERIE PHARMA2.81%
NATERA INC2.64%
GLAUKOS CORP2.53%
Bridgebio Ph2.16%
NBIX2.14%
Other2.13%

Portfolio allocation by GICS sector

Sectors3
Healthcare73.84%
Unknown25.68%
Financial Services0.48%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used